Cardiovascular drug therapy in women

Area of Science:

• Pharmacology
• Cardiology
• Women's Health

Background:

• Cardiovascular disease is a leading cause of death in American women.
• Historically, women were underrepresented in clinical trials for cardiovascular drugs.
• Existing drug data often predates current regulations mandating female inclusion.

Purpose of the Study:

• To provide advanced practice nurses with current information on cardiovascular drug use in women.
• To address the gap in readily available clinical data for female patients.
• To guide evidence-based drug therapy decisions for women.

Main Methods:

• Review of unique biological features of women relevant to drug therapy.
• Explanation of pharmacokinetic processes (absorption, distribution, clearance) in women.
• Analysis of evidence from major trials on cardiovascular conditions in women.
• Consideration of physiological changes during the menstrual cycle and pregnancy.

Main Results:

• Lack of comprehensive data for many cardiovascular drugs tested before new regulations.
• Identification of unique pharmacokinetic and pharmacodynamic considerations in women.
• Analysis of drug efficacy and safety across various cardiovascular conditions (ACS, heart failure, dyslipidemia, AFib, hypertension).

Conclusions:

• Advanced practice nurses need current data to effectively prescribe cardiovascular drugs to women.
• Understanding women's unique physiology is crucial for safe and effective drug therapy.
• Recommendations for drug prescription are provided to improve clinical practice.